B-intervention	0	11	Progressive
I-intervention	12	22	resistance
I-intervention	23	31	training
O	32	34	to
O	35	42	prevent
B-condition	43	46	arm
I-condition	47	57	lymphedema
O	58	60	in
O	61	64	the
O	65	70	first
O	71	75	year
O	76	81	after
O	82	88	breast
O	89	95	cancer
O	96	103	surgery
O	103	104	:
O	105	112	Results
O	113	115	of
O	116	117	a
O	118	128	randomized
O	129	139	controlled
O	140	145	trial
O	145	146	.

O	147	155	Existing
O	156	164	research
O	165	173	suggests
O	174	178	that
O	179	190	progressive
O	191	201	resistance
O	202	210	training
O	211	212	(
O	212	215	PRT
O	215	216	)
O	217	222	after
O	223	229	breast
O	230	236	cancer
O	237	238	(
O	238	240	BC
O	240	241	)
O	242	249	surgery
O	250	252	is
O	253	257	safe
O	257	258	,
O	259	262	but
O	263	266	the
O	267	277	preventive
O	278	284	effect
O	285	287	on
O	288	291	arm
O	292	302	lymphedema
O	303	306	has
O	307	310	yet
O	311	313	to
O	314	316	be
O	317	327	determined
O	327	328	.

O	329	334	Women
O	335	339	aged
B-age	340	342	18
I-age	343	345	to
I-age	346	348	75
I-age	349	354	years
B-eligibility	355	358	who
I-eligibility	359	363	were
I-eligibility	364	374	undergoing
I-eligibility	375	377	BC
I-eligibility	378	385	surgery
I-eligibility	386	390	with
I-eligibility	391	399	axillary
I-eligibility	400	405	lymph
I-eligibility	406	410	node
I-eligibility	411	421	dissection
O	422	426	were
O	427	435	eligible
O	436	439	for
O	440	443	the
O	444	449	study
O	449	450	.

O	451	460	Recruited
O	461	463	on
O	464	467	the
O	468	471	day
O	472	474	of
O	475	482	surgery
O	482	483	,
O	484	496	participants
O	497	501	were
O	502	511	allocated
O	512	514	to
O	515	527	intervention
O	528	530	or
B-control	531	536	usual
I-control	537	541	care
O	542	544	by
O	545	553	computer
O	554	567	randomization
O	567	568	.

O	569	572	The
O	573	585	intervention
O	586	595	consisted
O	596	598	of
O	599	602	PRT
O	603	604	3
O	605	610	times
O	611	614	per
O	615	619	week
O	619	620	:
O	621	623	in
O	624	627	the
O	628	633	first
O	634	636	20
O	637	642	weeks
O	643	645	as
O	646	647	a
O	648	658	supervised
O	659	664	group
O	665	673	exercise
O	674	677	and
O	678	680	in
O	681	684	the
O	685	689	last
O	690	692	30
O	693	698	weeks
O	699	701	as
O	702	703	a
O	704	708	self
O	708	709	-
O	709	721	administered
O	722	730	exercise
O	730	731	.

O	732	735	The
O	736	743	primary
O	744	751	outcome
O	752	755	was
B-outcome-Measure	756	759	arm
I-outcome-Measure	760	770	lymphedema
O	770	771	,
O	772	777	which
O	778	781	was
O	782	789	defined
O	790	792	as
O	793	794	a
O	795	796	>
O	796	797	3
O	797	798	%
O	799	807	increase
O	808	810	in
O	811	814	the
O	815	824	interlimb
O	825	831	volume
O	832	842	difference
O	843	845	by
O	846	851	water
O	852	864	displacement
O	864	865	.

O	866	878	Measurements
O	879	883	were
O	884	888	made
O	889	891	at
O	892	895	the
O	896	904	baseline
O	905	908	and
O	909	911	at
O	912	913	a
O	914	916	12
O	916	917	-
O	917	922	month
O	923	929	follow
O	929	930	-
O	930	932	up
O	933	935	by
O	936	952	physiotherapists
O	953	960	blinded
O	961	963	to
O	964	969	group
O	970	980	allocation
O	980	981	.

O	982	990	Analyses
O	991	993	of
O	994	1001	effects
O	1002	1010	included
O	1011	1012	t
O	1013	1018	tests
O	1019	1022	and
O	1023	1033	regression
O	1034	1040	models
O	1040	1041	;
O	1042	1049	missing
O	1050	1054	data
O	1055	1059	were
O	1060	1069	addressed
O	1070	1072	by
O	1073	1081	multiple
O	1082	1092	imputation
O	1092	1093	.

O	1094	1099	Among
O	1100	1103	the
B-total-participants	1104	1107	158
O	1108	1118	randomized
O	1119	1124	women
O	1124	1125	,
O	1126	1128	no
O	1129	1133	mean
O	1134	1139	group
O	1140	1150	difference
O	1151	1154	was
O	1155	1160	found
O	1161	1163	in
B-outcome	1164	1167	arm
I-outcome	1168	1174	volume
O	1175	1176	(
O	1176	1177	0
O	1177	1178	.
O	1178	1179	3
O	1179	1180	%
O	1180	1181	;
O	1182	1184	95
O	1184	1185	%
O	1186	1196	confidence
O	1197	1205	interval
O	1205	1206	,
O	1207	1208	-
O	1208	1209	1
O	1209	1210	.
O	1210	1211	7
O	1211	1212	%
O	1213	1215	to
O	1216	1217	2
O	1217	1218	.
O	1218	1219	3
O	1219	1220	%
O	1220	1221	)
O	1222	1224	or
B-outcome	1225	1235	lymphedema
I-outcome	1236	1245	incidence
O	1246	1247	(
O	1247	1255	adjusted
O	1256	1260	odds
O	1261	1266	ratio
O	1266	1267	,
O	1268	1269	1
O	1269	1270	.
O	1270	1271	2
O	1271	1272	;
O	1273	1275	95
O	1275	1276	%
O	1277	1287	confidence
O	1288	1296	interval
O	1296	1297	,
O	1298	1299	0
O	1299	1300	.
O	1300	1301	5
O	1301	1302	-
O	1302	1303	2
O	1303	1304	.
O	1304	1305	8
O	1305	1306	)
O	1306	1307	.

O	1308	1312	None
O	1313	1315	of
O	1316	1319	the
O	1320	1332	participants
O	1333	1339	exited
O	1340	1343	the
O	1344	1351	program
O	1352	1359	because
O	1360	1362	of
O	1363	1370	adverse
O	1371	1377	events
O	1377	1378	.

O	1379	1383	This
O	1384	1389	study
O	1390	1398	provides
O	1399	1401	no
O	1402	1410	evidence
O	1411	1415	that
O	1416	1419	PRT
O	1420	1423	can
O	1424	1431	prevent
O	1432	1435	arm
O	1436	1446	lymphedema
O	1447	1449	in
O	1450	1453	the
O	1454	1459	first
O	1460	1464	year
O	1465	1470	after
O	1471	1473	BC
O	1473	1474	,
O	1475	1478	but
O	1479	1482	the
O	1483	1490	results
O	1491	1502	corroborate
O	1503	1506	the
O	1507	1517	importance
O	1518	1521	and
O	1522	1528	safety
O	1529	1531	of
O	1532	1542	resistance
O	1543	1551	training
O	1552	1555	for
O	1556	1564	patients
O	1564	1565	,
O	1566	1575	including
O	1576	1581	women
O	1582	1584	at
O	1585	1589	high
O	1590	1594	risk
O	1595	1598	for
O	1599	1609	lymphedema
O	1609	1610	.
